PDT Partners LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• PDT Partners LLC initiated a position in ANI Pharmaceuticals by purchasing 45,442 shares worth approximately $3.76 million, representing about 0.20% of the company. Institutional investors collectively own 76.05% of ANIP.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in earnings per share versus the $2.04 consensus estimate and $266.04 million in revenue, up 25.8% year over year. The company provided fiscal 2026 EPS guidance of $9.19 to $9.69.
• ANIP shares opened at $74.56, near the lower end of their 12-month range of $70.15 to $99.50. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $105.83, although several firms recently lowered ratings or target prices.

PDT Partners LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,442 shares of the specialty pharmaceutical company's stock, valued at approximately $3,762,000. PDT Partners LLC owned approximately 0.20% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ANIP. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. lifted its holdings in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in ANI Pharmaceuticals in the 4th quarter worth approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the second quarter worth approximately $50,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the firm's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the sale, the chief financial officer directly owned 174,693 shares in the company, valued at $14,213,022.48. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president owned 74,424 shares in the company, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 24,387 shares of company stock worth $1,947,625. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $74.56 on Thursday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The business's 50 day moving average is $79.93 and its two-hundred day moving average is $78.75. The company has a market cap of $1.71 billion, a P/E ratio of 16.07 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12 month low of $70.15 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to analysts' expectations of $260.13 million. During the same period in the prior year, the business earned $1.80 earnings per share. ANI Pharmaceuticals's revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ANIP. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Guggenheim decreased their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a report on Monday, August 10th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source